Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Medical Imaging Deals Abound

by | Oct 19, 2015 8:57 am | Laboratories, MRI & Dialysis, Private Equity

Only half way through October, we’ve seen three transactions targeting a medical imaging company in our Laboratories, MRI & Dialysis sector. That brings to 10 the number of imaging targets in 2015, out of the current total of 39 deals recorded in the sector. It began on October 1, with Konica Minolta Medical Imaging USA’s announcement that it was buying Viztek, LLC, a digital software and hardware imaging company, for an undisclosed price. Another optical giant, Toshiba Medical Systems Corporation, announced its acquisition of Olea Medical SA, a French medical imaging applications company, for an undisclosed price. The next day, Digirad Corporation (NASDAQ: DRAD) paid $36... Read More »

Q3:15 Health Care M&A, by Spending

by | Oct 19, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we shared our data on health care M&A by sector in the third quarter of 2015. Here’s a look at the same sectors, by share of the dollars spent. If you’ve been following health care M&A at all, you won’t be surprised that the Managed Care sector (health insurers) accounts for about 50% of the $198 billion spent. That total, by the way, is also a new quarterly record. Look for The Health Care M&A Report, Third Quarter, for more in-depth analysis by sector. Read More »

Compassus Expands Its Hospice Footprint

by | Oct 12, 2015 8:59 am | Home Health & Hospice, Private Equity

Compassus, formerly known as Hospice Compassus, last week announced its acquisition of Hospice Advantage, based in Bay City, Michigan, from Sentinel Capital Partners. Hospice Advantage offers end-of-life care with locations in Alabama, Georgia, Illinois, Indiana, Kansas, Michigan, Minnesota, Mississippi, Missouri, Oklahoma, Pennsylvania, South Carolina, Tennessee and Wisconsin. The service area of the combined company, which will operate as Compassus, will extend to 150 locations in 28 states, serving more than 30,000 patients and their families each year. This acquisition builds on Compassus’s acquisition of Life Choice Hospice in February 2015. Financial terms were not disclosed in... Read More »

PharMEDium Healthcare Sold for $2.6 Billion

by | Oct 12, 2015 8:58 am | Other Services, Private Equity

Last week’s largest deal came from AmerisourceBergen Corporation (NYSE: ABC). The pharmaceutical distributor agreed to pay $2.575 billion for PharMEDium Healthcare Holdings, a portfolio company of Clayton, Dublier & Rice. PharMEDium  provides outsourced compounded sterile preparations to acute care hospitals in the United States. It maintains four compounding facilities and serves over 3,000 U.S. hospitals.  The acquisition is expected to be $0.22 to $0.26 accretive to ABC’s adjusted EPS in fiscal 2016 on a net basis, and is expected to generate approximately $30 million in synergies by fiscal 2018. Read More »

Managed Care Deals Keep on Coming

by | Oct 12, 2015 8:57 am | Managed Care

Even in a slow week for health care M&A, two transactions in the Managed Care sector surfaced. They weren’t the mega-mergers announced a few months ago, but they’re a sign this segment is still consolidating, even on the lower end of the scale. On October 8, Nassau Reinsurance Group, which was launched last April and backed by Golden Gate Capital, announced it would acquire the Traditional Insurance business of Universal American Corp. (NYSE: UAM). The assets consist of a closed block of insurance products, including Medicare supplement, other senior health insurance, specialty health insurance and life insurance products that include long-term care policies. Nassau agreed... Read More »

Q3:15 Health Care M&A, By Sector

by | Oct 12, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Rehabilitation

Health care M&A in the third quarter was quite robust, with 385 transations reported across 13 sectors. That’s a new record for any third quarter, by the way. We’ll have the full break-out in The Health Care M&A Report, Third Quarter 2015, due to be published by the end of this month. In the meantime, here’s how the sectors fared in Q3:15. Read More »

Teva Can’t Stop Buying

by | Oct 5, 2015 8:59 am | Pharmaceuticals

With six acquisitions already on the books in 2015, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would pay $2.3 billion for Representaciones e Investigaciones Médicas (Rimsa), a leading pharmaceutical manufacturing and distribution company in Mexico. Also associated with this deal is a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe. With this acquisition, Teva becomes one of the top pharmaceutical companies in Mexico, which is the second largest market in Latin America and one of the top five emerging markets globally. The company expects the deal will yield substantial and achievable synergies and offer... Read More »

Medtronic Acquires Lazarus Effect

by | Oct 5, 2015 8:58 am | Medical Devices

You have to admit, naming a company Lazarus Effect sets up some big expectations. Medtronic plc (NYSE: MDT) had that in mind, no doubt, when it paid $100 million for medical device maker Lazarus Effect in late September. The target’s lead product is the Lazarus Cover™, which complements Medtronic’s Solitaire™ stent retriever platform. The technology is designed to address clinical needs with a novel nitinol “mesh cover” that folds over a stent retriever device during clot retrieval and wraps the stent with the clot inside. Medtronic will report the Lazarus Effect product line as part of its Neurovascular division within the Restorative Therapies Group. Read More »